|
|
|
|
|
20.03.26 - 11:51
|
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that two articles have been published back-to-back in the same issue of The Lancet Haematology. The articles detail data from the two randomized Phase 2 studies, CHAPTER-1 and RAPIDe-1, evaluating the efficacy and safety of deucrictibant, a potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist, in development for the prophylaxis and on-demand treatment of HAE attacks, respectively....
|
|
|
11.03.26 - 11:51
|
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from a Pharvaris-sponsored non-interventional, mixed methods, real-world study assessing the patient experience during acute HAE attacks across alternative endpoints used in clinical studies have been published in Clinical Reviews in Allergy & Immunology. The study evaluated the patient experience with HAE attack manifestations, and what constitutes meaningful changes in those manifestations, to support the inclusion of meaningful endpoints in clinical studies for on-demand treatment (ODT) of HAE attacks, such as RAPIDe-3 (NCT06343779)....
|
|
|
02.03.26 - 12:54
|
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations for the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, which took place from February 27-March 2, 2026, in Philadelphia, PA....
|
|
|
|
|
12.01.26 - 12:54
|
Pharvaris Outlines 2026 Strategic Priorities (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today outlined its strategic priorities for 2026....
|
|
|
10.12.25 - 17:36
|
BRAIN Biotech Aktie: Erfolg beim "BioIncubators" - Deucrictibant könnte FY27 zugelassen werden (Aktiencheck)
|
|
|
Frankfurt am Main (www.aktiencheck.de) - BRAIN Biotech-Aktienanalyse von der EQUI.TS GmbH:
Thomas Schießle und Daniel Großjohann, Aktienanalysten der EQUI.TS GmbH, stufen die Aktie der BRAIN Biotech AG (ISIN: DE0005203947, WKN: 520394, Ticker-Symbol: BNN) von "halten" auf "kaufen" hoch.
Gute Nachricht von Pharvaris B.V, die über vielversprechende Topline-Daten aus der pivotalen Phase III-Studie RAPIDe-3 berichtet habe (CN 03.12.25), so die Fachleute aus Frankfurt/M. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.12.25 - 12:54
|
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced RAPIDe-3 pivotal data confirming the potential of deucrictibant's differentiated profile for the on-demand treatment of HAE attacks. The data from Pharvaris' first pivotal Phase 3 study will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026....
|
|
|
|
|
|
|
|
|
12.11.25 - 12:54
|
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today reported financial results for the third quarter ended September 30, 2025, and provided a business update....
|
|
|
10.11.25 - 12:54
|
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the 2025 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), including data from two oral presentations and six posters, which took place from November 6-10, 2025, in Orlando, Fla....
|
|
|
23.10.25 - 12:54
|
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting (GlobeNewswire EN)
|
|
|
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10, in Orlando, Florida....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
